{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:03:12Z","timestamp":1788451392509,"version":"build-2803163510"},"reference-count":18,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    <ns4:bold>Background<\/ns4:bold>\n                    : Chronic telogen effluvium (CTE) may be primary or secondary to various causes, including drug reaction, nutritional deficiency and female pattern hair loss (FPHL).\u00a0 Oral minoxidil stimulates hair growth, and topical minoxidil is used in the treatment of FPHL and male androgenetic alopecia. minoxidil has not been used to treat CTE. This study aimed to assess the treatment of CTE with once daily oral minoxidil.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Methods<\/ns4:bold>\n                    : Women with a diagnosis of CTE based on &gt;6 month history of increased telogen hair shedding, no visible mid frontal scalp hair loss (Sinclair stage 1) and no hair follicle miniaturization on scalp biopsy were treated with once daily oral minoxidil.\u00a0 Hair shedding scores (HSS) at baseline, 6 and 12 months were analysed using the Wilcoxon rank sum test for pair-wise comparisons.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Results<\/ns4:bold>\n                    : Thirty-six women were treated with oral minoxidil (range, 0.25-2.5 mg) daily for 6 months.\u00a0 Mean age was 46.9 years (range 20-83), HSS at baseline was 5.64, and duration of diagnosis was 6.55 years (range 1-27).\u00a0 There was a reduction in mean HSS scores from baseline to 6 months of 1.7 (p&lt;0.001) and baseline to 12 months of 2.58 (p&lt;0.001). Five women who described trichodynia at baseline, noted improvement or resolution within 3 months.\u00a0 Mean change in blood pressure was minus 0.5 mmHg systolic and plus 2.1 mmHg diastolic.\u00a0 Two patients developed transient postural dizziness that resolved with continued treatment.\u00a0 One patient developed ankle oedema.\u00a0 Thirteen women developed facial hypertrichosis.\u00a0 For 6 patients this was mild and did not require treatment; 4 had waxing of their upper lip or forehead; 3 had laser hair removal.\u00a0 No patients developed any haematological abnormality.\u00a0 All 36 women completed 12 months of treatment.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Conclusions<\/ns4:bold>\n                    : Once daily oral minoxidil appears to reduce hair shedding in CTE.\u00a0 Placebo controlled studies are recommended to further assess this response.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.11775.1","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T17:27:19Z","timestamp":1504718839000},"page":"1650","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study"],"prefix":"10.12688","volume":"6","author":[{"given":"Eshini","family":"Perera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-1428","authenticated-orcid":false,"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"846-8","DOI":"10.1111\/bjd.13873","article-title":"Hair shedding in women: how much is too much?","volume":"173","author":"R Sinclair","year":"2015","journal-title":"Br J Dermatol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"8-18","DOI":"10.1046\/j.1365-4362.1999.00003.x","article-title":"Diffuse hair loss.","volume":"38 Suppl 1","author":"R Sinclair","year":"1999","journal-title":"Int J Dermatol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"389-5","DOI":"10.1046\/j.1365-2230.2002.01080.x","article-title":"Telogen effluvium.","volume":"27","author":"S Harrison","year":"2002","journal-title":"Clin Exp Dermatol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"899-906","DOI":"10.1016\/S0190-9622(96)90113-9","article-title":"Chronic telogen effluvium: increased scalp hair shedding in middle-aged women.","volume":"35","author":"D Whiting","year":"1996","journal-title":"J Am Acad Dermatol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"63.1-63.100","DOI":"10.1002\/9781444317633.ch66","article-title":"Disorders of Hair","author":"A Messenger","year":"2010"},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"163-7","DOI":"10.1111\/j.1440-0960.2010.00654.x","article-title":"Chronic telogen effluvium is due to a reduction in the variance of anagen duration.","volume":"51","author":"S Gilmore","year":"2010","journal-title":"Australas J Dermatol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"865-869","DOI":"10.1136\/bmj.317.7162.865","article-title":"Male pattern androgenetic alopecia.","volume":"317","author":"R Sinclair","year":"1998","journal-title":"BMJ."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"12-6","DOI":"10.1016\/j.jaad.2004.05.040","article-title":"Chronic telogen effluvium: a study of 5 patients over 7 years.","volume":"52","author":"R Sinclair","year":"2005","journal-title":"J Am Acad Dermatol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"868-73","DOI":"10.1111\/ced.12406","article-title":"Chronic telogen effluvium and female pattern hair loss are separate and distinct forms of alopecia: a histomorphometric and immunohistochemical analysis.","volume":"39","author":"C Bittencourt","year":"2014","journal-title":"Clin Exp Dermatol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"723-31","DOI":"10.1016\/S0733-8635(05)70398-3","article-title":"Chronic telogen effluvium.","volume":"14","author":"D Whiting","year":"1996","journal-title":"Dermatol Clin."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"842-843","DOI":"10.1111\/j.1365-4632.2004.02034.x","article-title":"Chronic telogen effluvium or early androgenetic alopecia?","volume":"43","author":"R Sinclair","year":"2004","journal-title":"Int J Dermatol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1488-90","DOI":"10.1001\/archderm.1987.01660350088019","article-title":"Evaluation of oral minoxidil in the treatment of alopecia areata.","volume":"123","author":"V Fiedler-Weiss","year":"1987","journal-title":"Arch Dermatol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"691-693","DOI":"10.1046\/j.1365-4362.2003.01847.x","article-title":"The presence of trichodynia in patients with telogen effluvium and androgenetic alopecia.","volume":"42","author":"I Kivan\u00e7-Altunay","year":"2003","journal-title":"Int Dermatol."},{"key":"ref-14","doi-asserted-by":"crossref","first-page":"1123-4","DOI":"10.1001\/archderm.135.9.1123","article-title":"Chronic telogen effluvium: incidence, clinical and biochemical features, and treatment.","volume":"135","author":"M Garcia-Hernandez","year":"1999","journal-title":"Arch Dermatol."},{"key":"ref-15","first-page":"27","article-title":"Treatment of female pattern hair loss with oral minoxidil.","volume":"57","author":"R Sinclair","year":"2016","journal-title":"Austral J Dermatol."},{"key":"ref-16","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12350","article-title":"Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil.","author":"X Yang","year":"2015","journal-title":"Australas J Dermatol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"12-18","DOI":"10.1111\/j.1365-2133.2011.10630.x","article-title":"Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness.","volume":"165","author":"R Sinclair","year":"2011","journal-title":"Br J Dermatol."},{"key":"ref-18","doi-asserted-by":"publisher","DOI":"10.5256\/f1000research.11775.d176418","article-title":"Dataset 1 in: Treatment of Chronic Telogen Effluvium with Oral Minoxidil.","author":"R Sinclair","year":"2017","journal-title":"F1000Research."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-1650\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-1650\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-1650\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T08:27:05Z","timestamp":1544084825000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-1650\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":18,"URL":"https:\/\/doi.org\/10.12688\/f1000research.11775.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.12721.r25750","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.12721.r26886","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.12721.r26886","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.12721.r25750","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,6]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-1650\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.12721.r25750, Victoria M.L. Jolliffe, Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London, UK, 21 Sep 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-1650\/v1#referee-response-25750","order":0,"name":"referee-response-25750","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.12721.r26886, Alex J. Chamberlain, Alfred Health, Melbourne, Vic, Australia, 06 Nov 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-1650\/v1#referee-response-26886","order":1,"name":"referee-response-26886","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}